肝细胞GSTM2通过抑制ASK1信号预防非酒精性脂肪性肝炎
本研究探讨谷胱甘肽S-转移酶Mu 2(GSTM2)在非酒精性脂肪性肝炎(NASH)中的作用。RNA-seq分析显示NASH进展中GSTM2显著下调,功能获得/缺失实验表明肝细胞GSTM2缺失加重胰岛素抵抗、脂肪变性、炎症和纤维化。机制上GSTM2直接结合ASK1 N端抑制其二聚化和磷酸化,从而抑制下游JNK/p38通路。
要点
- GSTM2在NASH进展中显著下调,是NASH的敏感响应因子和有效抑制因子。
- 肝细胞GSTM2缺失加重高脂饮食及高脂/高胆固醇饮食诱导的胰岛素抵抗、脂肪变性、炎症和纤维化。
- GSTM2通过直接结合ASK1 N端抑制其二聚化和磷酸化,阻断下游JNK/p38信号通路。
核心结论
- 肝细胞GSTM2是阻止NASH进展的内源性抑制因子,通过阻断ASK1 N端二聚化和磷酸化发挥作用。
- 激活GSTM2有望成为NASH的治疗策略。
研究设计与样本
- 采用多种RNA-seq分析鉴定NASH中肝脏GSTM2表达。
- 采用体外和体内功能获得或缺失方法研究GSTM2在NASH中的作用和分子机制。
主要发现
- NASH进展过程中GSTM2显著下调。
- 肝细胞GSTM2缺失显著加重高脂饮食和高脂/高胆固醇饮食诱导的胰岛素抵抗、肝脏脂肪变性、炎症和纤维化。
- GSTM2通过直接与ASK1相互作用维持MAPK通路信号传导。
- GSTM2直接结合ASK1 N端区域,抑制ASK1 N端二聚化,从而在代谢功能障碍条件下抑制ASK1磷酸化及下游JNK/p38信号通路活化。
临床怎么用
- GSTM2可作为NASH的潜在治疗靶点,增加其活性可能对NASH治疗有益。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND & AIMS: Non-alcoholic fatty liver disease (NAFLD) has become the most common chronic liver disease worldwide. The advanced stage of NAFLD, non-alcoholic steatohepatitis (NASH), has been recognized as a leading cause of end-stage liver injury for which there are no FDA-approved therapeutic options. Glutathione S-transferase Mu 2 (GSTM2) is a phase II detoxification enzyme. However, the roles of GSTM2 in NASH have not been elucidated. METHODS: Multiple RNA-seq analyses were used to identify hepatic GSTM2 expression in NASH. In vitro and in vivo gain- or loss-of-function approaches were used to investigate the role and molecular mechanism of GSTM2 in NASH. RESULTS: We identified GSTM2 as a sensitive responder and effective suppressor of NASH progression. GSTM2 was significantly downregulated during NASH progression. Hepatocyte GSTM2 deficiency markedly aggravated insulin resistance, hepatic steatosis, inflammation and fibrosis induced by a high-fat diet and a high-fat/high-cholesterol diet. Mechanistically, GSTM2 sustained MAPK pathway signaling by directly interacting with apoptosis signal-regulating kinase 1 (ASK1). GSTM2 directly bound to the N-terminal region of ASK1 and inhibited ASK1 N-terminal dimerization to subsequently repress ASK1 phosphorylation and the activation of its downstream JNK/p38 signaling pathway under conditions of metabolic dysfunction. CONCLUSIONS: These data demonstrated that hepatocyte GSTM2 is an endogenous suppressor that protects against NASH progression by blocking ASK1 N-terminal dimerization and phosphorylation. Activating GSTM2 holds promise as a therapeutic strategy for NASH. CLINICAL TRIAL NUMBER: IIT-2021-277. LAY SUMMARY: New therapeutic strategies for non-alcoholic steatohepatitis are urgently needed. We identified that the protein GSTM2 exerts a protective effect in response to metabolic stress. Therapies that aim to increase the activity of GSTM2 could hold promise for the treatment of non-alcoholic steatohepatitis.
引用
- Lan T, Hu Y, Hu F, et al. Hepatocyte glutathione S-transferase mu 2 prevents non-alcoholic steatohepatitis by suppressing ASK1 signaling. J Hepatol. 2021. PMID: 34656650. doi:10.1016/j.jhep.2021.09.040
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。